Novavax to Participate in Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Novavax (Nasdaq: NVAX), a biotechnology company specializing in vaccines, announced participation in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 p.m. ET. The event will feature discussions about its COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John Trizzino. A replay of the session will be available on the company’s website for 90 days. Novavax aims to combat serious infectious diseases through innovative vaccines and is advancing its COVID-19 and NanoFlu vaccine candidates in clinical trials.

GAITHERSBURG, Md., May 27, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat and host meetings with investors at the upcoming Jefferies Virtual Healthcare Conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date:	Tuesday, June 1, 2021
Time:	1:30 – 1:55 p.m. Eastern Time (ET)
Novavax participants:	Gregory M. Glenn, M.D., President, Research and Development and John Trizzino, Executive Vice President, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer

A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:     
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Laura Keenan | 202-709-7521
Amy Speak | 617-420-2461
media@novavax.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-virtual-healthcare-conference-301300365.html

SOURCE Novavax, Inc.

FAQ

What is Novavax discussing at the Jefferies Virtual Healthcare Conference?

Novavax will discuss its COVID-19 vaccine candidate, NVX-CoV2373.

When is Novavax's fireside chat scheduled?

The fireside chat is scheduled for June 1, 2021, at 1:30 p.m. ET.

Who are the participants from Novavax at the conference?

Participants include Gregory M. Glenn, M.D., and John Trizzino.

How can I access the replay of Novavax's fireside chat?

The replay will be available on Novavax's events page for 90 days after the conference.

What vaccine candidates is Novavax currently working on?

Novavax is working on NVX-CoV2373 for COVID-19 and NanoFlu™, a quadrivalent influenza vaccine.